These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 26238598)

  • 1. Defining the minimal clinically important difference (MCID) of the Heinrichs-carpenter quality of life scale (QLS).
    Falissard B; Sapin C; Loze JY; Landsberg W; Hansen K
    Int J Methods Psychiatr Res; 2016 Jun; 25(2):101-11. PubMed ID: 26238598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia.
    Naber D; Hansen K; Forray C; Baker RA; Sapin C; Beillat M; Peters-Strickland T; Nylander AG; Hertel P; Andersen HS; Eramo A; Loze JY; Potkin SG
    Schizophr Res; 2015 Oct; 168(1-2):498-504. PubMed ID: 26232241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study.
    Naber D; Baker RA; Eramo A; Forray C; Hansen K; Sapin C; Peters-Strickland T; Nylander AG; Hertel P; Nitschky Schmidt S; Loze JY; Potkin SG
    Schizophr Res; 2018 Feb; 192():205-210. PubMed ID: 28433498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abbreviated quality of life scales for schizophrenia: comparison and utility of two brief community functioning measures.
    Fervaha G; Foussias G; Siddiqui I; Agid O; Remington G
    Schizophr Res; 2014 Apr; 154(1-3):89-92. PubMed ID: 24630140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes.
    Dunayevich E; Sethuraman G; Enerson M; Taylor CC; Lin D
    Schizophr Res; 2006 Sep; 86(1-3):300-8. PubMed ID: 16860974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
    Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; Markwick A; Lloyd H; Dunn G
    Health Technol Assess; 2006 May; 10(17):iii-iv, ix-xi, 1-165. PubMed ID: 16707074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of aripiprazole vs standard-of-care in the management of community-treated patients with schizophrenia: STAR study.
    King D; Knapp M; Thomas P; Razzouk D; Loze JY; Kan HJ; van Baardewijk M
    Curr Med Res Opin; 2011 Feb; 27(2):365-74. PubMed ID: 21166610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
    Tollefson GD; Andersen SW
    J Clin Psychiatry; 1999; 60 Suppl 5():23-9; discussion 30. PubMed ID: 10192404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimal Clinically Important Differences (MCID) in Assessing Outcomes of Post-Traumatic Stress Disorder.
    Stefanovics EA; Rosenheck RA; Jones KM; Huang G; Krystal JH
    Psychiatr Q; 2018 Mar; 89(1):141-155. PubMed ID: 28634644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia.
    Wehmeier PM; Kluge M; Schneider E; Schacht A; Wagner T; Schreiber W
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):703-12. PubMed ID: 17289237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study.
    Kerwin R; Millet B; Herman E; Banki CM; Lublin H; Pans M; Hanssens L; L'Italien G; McQuade RD; Beuzen JN
    Eur Psychiatry; 2007 Oct; 22(7):433-43. PubMed ID: 17555947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate.
    Potkin SG; Loze JY; Forray C; Baker RA; Sapin C; Peters-Strickland T; Beillat M; Nylander AG; Hertel P; Nitschky Schmidt S; Eramo A; Hansen K; Naber D
    Int J Neuropsychopharmacol; 2017 Jan; 20(1):40-49. PubMed ID: 27927736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia.
    Witte MM; Case MG; Schuh KJ; Ascher-Svanum H
    Curr Med Res Opin; 2012 Mar; 28(3):315-23. PubMed ID: 22236137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preference of medicine and patient-reported quality of life in community-treated schizophrenic patients receiving aripiprazole vs standard of care: results from the STAR study.
    Taylor D; Hanssens L; Loze JY; Pans M; L'Italien G; Marcus RN
    Eur Psychiatry; 2008 Aug; 23(5):336-43. PubMed ID: 18423987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life in stable schizophrenia: the relative contributions of disorganization and cognitive dysfunction.
    Sigaudo M; Crivelli B; Castagna F; Giugiario M; Mingrone C; Montemagni C; Rocca G; Rocca P
    Schizophr Res; 2014 Mar; 153(1-3):196-203. PubMed ID: 24485197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing health status over time: impact of recall period and anchor question on the minimal clinically important difference of copd health status tools.
    Alma HJ; de Jong C; Jelusic D; Wittmann M; Schuler M; Kollen BJ; Sanderman R; Schultz K; Kocks JWH; Van der Molen T
    Health Qual Life Outcomes; 2018 Jun; 16(1):130. PubMed ID: 29940980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial.
    Revicki DA; Genduso LA; Hamilton SH; Ganoczy D; Beasley CM
    Qual Life Res; 1999 Aug; 8(5):417-26. PubMed ID: 10474283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: results from QUALIFY.
    Potkin SG; Loze JY; Forray C; Baker RA; Sapin C; Peters-Strickland T; Beillat M; Nylander AG; Hertel P; Steen Andersen H; Eramo A; Hansen K; Naber D
    Int Clin Psychopharmacol; 2017 May; 32(3):147-154. PubMed ID: 28252452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is the Minimum Clinically Important Difference for the WOMAC Index After TKA?
    Clement ND; Bardgett M; Weir D; Holland J; Gerrand C; Deehan DJ
    Clin Orthop Relat Res; 2018 Oct; 476(10):2005-2014. PubMed ID: 30179956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone.
    Phillips GA; Van Brunt DL; Roychowdhury SM; Xu W; Naber D
    J Clin Psychiatry; 2006 Sep; 67(9):1397-403. PubMed ID: 17017826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.